Anavex Life Sciences Income Statement

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021	2020 - 2016
Selling, General & Admin	13.95	11.16	12.16	13.14	9.15	Upgrade
Research & Development	36.81	39.42	40.88	34.52	28.31	Upgrade
Operating Expenses	50.76	50.59	53.05	47.66	37.46	Upgrade
Operating Income	-50.76	-50.59	-53.05	-47.66	-37.46	Upgrade
Interest & Investment Income	4.68	7.32	6.52	0.95	0.03	Upgrade
Currency Exchange Gain (Loss)	-0.33	0.19	-0.04	-0.9	-0.27	Upgrade
Other Non Operating Income (Expenses)	0.04	0.08	-0.94	-	0.05	Upgrade
EBT Excluding Unusual Items	-46.38	-43	-47.51	-47.62	-37.64	Upgrade
Pretax Income	-46.38	-43	-47.51	-47.62	-37.64	Upgrade
Income Tax Expense	-	-	-	0.36	0.27	Upgrade
Net Income	-46.38	-43	-47.51	-47.98	-37.91	Upgrade
Net Income to Common	-46.38	-43	-47.51	-47.98	-37.91	Upgrade
Shares Outstanding (Basic)	85	83	80	77	70	Upgrade
Shares Outstanding (Diluted)	85	83	80	77	70	Upgrade
Shares Change (YoY)	2.18%	4.61%	3.74%	10.18%	19.95%	Upgrade
EPS (Basic)	-0.54	-0.52	-0.60	-0.62	-0.54	Upgrade
EPS (Diluted)	-0.54	-0.52	-0.60	-0.62	-0.54	Upgrade
EBIT	-50.76	-50.59	-53.05	-47.66	-37.46	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.